Journal of Nuclear Medicine October 2025, jnumed.125.270151; DOI: https://doi.org/10.2967/jnumed.125.270151 ...
Journal of Nuclear Medicine October 2025, jnumed.125.270242; DOI: https://doi.org/10.2967/jnumed.125.270242 ...
Journal of Nuclear Medicine October 2025, jnumed.124.269188; DOI: https://doi.org/10.2967/jnumed.124.269188 ...
Journal of Nuclear Medicine September 2025, jnumed.125.270391; DOI: https://doi.org/10.2967/jnumed.125.270391 ...
Journal of Nuclear Medicine September 2025, jnumed.125.269636; DOI: https://doi.org/10.2967/jnumed.125.269636 ...
Radioimmunotherapy using 225Ac, a highly cytotoxic α-particle emitter, has potential for treating advanced breast cancer, especially human epidermal growth factor receptor 2 (HER2)–positive cases. We ...
Results: The patients underwent 1-2 cycles of TANDEM PRLT with 177 Lu (5.05 ± 1.09 GBq) and 225 Ac (6.87 ± 3.14 MBq) per cycle, receiving 16 BTX treatments. All patients were heavily pre-treated, with ...
Introduction: Objectives: Neuroinflammation, a response of the innate immune system to pathological conditions, such as infection, toxin accumulation, and trauma in the central nervous system (CNS), ...
Journal of Nuclear Medicine May 2025, jnumed.125.269533; DOI: https://doi.org/10.2967/jnumed.125.269533 ...
Journal of Nuclear Medicine May 2025, jnumed.124.269227; DOI: https://doi.org/10.2967/jnumed.124.269227 ...
Journal of Nuclear Medicine April 2025, jnumed.124.269132; DOI: https://doi.org/10.2967/jnumed.124.269132 ...
Journal of Nuclear Medicine April 2025, jnumed.124.268980; DOI: https://doi.org/10.2967/jnumed.124.268980 ...